Misonix Names Leading Medical Device Executive Gwen Watanabe to Board of Directors
July 19 2018 - 7:30AM
Misonix, Inc. (NASDAQ:MSON) (“Misonix” or the “Company”), a
provider of minimally-invasive therapeutic ultrasonic medical
devices that enhance clinical outcomes, today announced the
appointment of Gwen Watanabe to its Board of Directors. Ms.
Watanabe replaces John Gildea, the founding principal of Gildea
Management Co., who has retired from his position on the Board of
Directors.
“Gwen is a highly respected executive in the
medical device sector who brings outstanding entrepreneurial skills
to the Misonix Board as well as a proven, long-term track record of
success in mergers and acquisitions at Teleflex,” stated Stavros
Vizirgianakis, President and Chief Executive Officer of Misonix.
“The ongoing execution of our cohesive strategy to grow Misonix's
leading ultrasonic surgical product platform is providing the
Company with a solid foundation to continue expanding market share
domestically as well as abroad. As we pursue the next phase of
inorganic and organic growth for Misonix, we are confident Gwen’s
presence on the Board of Directors will be tremendously valuable in
helping the Company achieve our goals for sustainable revenue
growth and profitability, as well as the enhancement of long-term
shareholder value.”
Ms. Watanabe commented, “I am very excited at
the opportunity to join the Misonix Board of Directors and be part
of a fast-growing company that is leveraging its unique proprietary
ultrasonic technology to bring to market medical devices that
deliver demonstrated clinical benefits and improve patient
outcomes. I look forward to sharing the experience and business
relationships built over my career working with medical device
start-ups and large public organizations to offer sound business
counsel to Misonix as the Company continues to pursue its strategic
growth initiatives and expand its leadership position in the
ultrasound medical device industry.”
Stavros Vizirgianakis added, “I want to thank
John Gildea for his many contributions and service to the Board and
the Company over the last fourteen years. His leadership and
financial expertise were instrumental in guiding Misonix
through a period of significant change and positioning the
Company for continued growth in the future.”
Gwen Watanabe has over 24 years of financial and
executive management experience in the medical device industry. Ms.
Watanabe presently serves as the vice president of global corporate
development, strategy, and strategic partnerships for Teleflex
Incorporated, a global provider of medical technology products,
where she also serves as a member of the executive leadership team,
reporting to Teleflex’s CEO. In her role at Teleflex, she is
responsible for worldwide corporate strategy and mergers and
acquisitions.
Prior to Teleflex, Ms. Watanabe served as
president and chief executive officer of medical device start-up
Hotspur Technology, Inc., where she led the company from initial
idea and design concept in 2009 through commercial release before
negotiating the successful sale of the business to Teleflex in
2012. From 2004 to 2009, Ms. Watanabe served as chief business
officer and chief financial officer of Nellix Endovascular, Inc., a
medical device start-up that she co-founded, where she successfully
raised venture capital financing and led a broad range of strategic
initiatives that resulted in the acquisition of the company by
Endologix. Earlier in her career, she served as a business
development manager at Bacchus Vascular, Inc. (acquired by
Covidien) and a project engineer at Aneurx, Inc. (acquired by
Medtronic). In addition, Ms. Watanabe was a general partner at
Saratoga Ventures V, L.P. and Saratoga Ventures VI, L.P., which
were all medical device venture funds.
Ms. Watanabe earned a Bachelor of Science degree
in Mechanical Engineering from the Massachusetts Institute of
Technology. She obtained her Master of Science in Mechanical
Engineering, Design Division from Stanford University and a Master
in Business Administration from Harvard University. She formerly
served on the Board of Directors for Hotspur Technologies, Catharos
Medical, NovaSom (formerly Sleep Solutions), Axis Surgical, Tibion,
American Red Cross of Hawaii and the Gift Foundation of Hawaii.
About Misonix, Inc.
Misonix, Inc. (NASDAQ:MSON) designs, develops,
manufactures and markets ultrasonic medical devices for the precise
removal of hard and soft tissue, including bone removal, wound
debridement and ultrasonic aspiration. Misonix is focused on
leveraging its proprietary ultrasonic technology to become the
standard of care in operating rooms and clinics around the world.
Misonix's proprietary ultrasonic medical devices are used in a
growing number of medical procedures, including spine surgery,
neurosurgery, orthopedic surgery, cosmetic surgery, laparoscopic
surgery, and other surgical and medical applications. At Misonix,
Better Matters to us. That is why throughout the Company’s history,
Misonix has maintained its commitment to medical technology
innovation and the development of ultrasonic surgical products that
radically improve patient outcomes. Additional information is
available on the Company's web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information
contained in this press release, content herein may contain
“forward looking statements” that are made pursuant to the Safe
Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based on management’s current
expectations and are subject to uncertainty and changes in
circumstances. Investors are cautioned that forward-looking
statements involve risks and uncertainties that could cause actual
results to differ materially from the statements made. These
factors include general economic conditions, delays and risks
associated with the performance of contracts, risks associated with
international sales and currency fluctuations, uncertainties as a
result of research and development, acceptable results from
clinical studies, including publication of results and
patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new
products, potential acquisitions, consumer and industry acceptance,
litigation and/or court proceedings, including the timing and
monetary requirements of such activities, the timing of finding
strategic partners and implementing such relationships, regulatory
risks including approval of pending and/or contemplated 510(k)
filings, the ability to achieve and maintain profitability in the
Company’s business lines, the impact of the pending investigation
by the Department of Justice and Securities Exchange Commission,
and other factors discussed in the Company’s Annual Report on Form
10-K for the fiscal year ended June 30, 2017, subsequent Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K. The Company
disclaims any obligation to update its forward-looking
relationships.
Contact: |
|
|
Joe
Dwyer Chief
Financial Officer Misonix, Inc.
631-694-9555 |
Joseph
Jaffoni, Norberto Aja, Jennifer Neuman JCIR 212-835-8500
or mson@jcir.com |
|
Misonix (NASDAQ:MSON)
Historical Stock Chart
From Aug 2024 to Sep 2024
Misonix (NASDAQ:MSON)
Historical Stock Chart
From Sep 2023 to Sep 2024